EORTC Group Phase II Study of Oral Etoposide for Pretreated Soft Tissue Sarcoma

H. Jan Keizer; Derek Crowther; Ole Steen Nielsen; Allan T. Van Oosterom; Javier Hornedo Muguiro; Christine Van Pottelberghe; Renier Somers; Thomas Tursz

doi:10.1080/13577149778371

Sarcoma (Jan 1997)

EORTC Group Phase II Study of Oral Etoposide for Pretreated Soft Tissue Sarcoma

H. Jan Keizer,
Derek Crowther,
Ole Steen Nielsen,
Allan T. Van Oosterom,
Javier Hornedo Muguiro,
Christine Van Pottelberghe,
Renier Somers,
Thomas Tursz

Affiliations

H. Jan Keizer: Leiden University Hospital, The Netherlands
Derek Crowther: University of Manchester, UK
Ole Steen Nielsen: Aarhus University Hospital, Denmark
Allan T. Van Oosterom: University Hospital of Antwerp, Belgium
Javier Hornedo Muguiro: Madrid Hospital Universitario, Spain
Christine Van Pottelberghe: EORTC Data Center, Belgium
Renier Somers: Netherlands Cancer Institute, The Netherlands
Thomas Tursz: Institut Gustave-Roussy, France

DOI: https://doi.org/10.1080/13577149778371
Journal volume & issue: Vol. 1, no. 2
pp. 99 – 101

Abstract

Read online

Purpose. This study investigates the efficacy and toxicity of daily oral etoposide in chemotherapy for non-heavily pretreated advanced and metastatic soft tissue sarcoma (STS).

Published in Sarcoma

ISSN: 1357-714X (Print); 1369-1643 (Online)
Publisher: Wiley
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://onlinelibrary.wiley.com/journal/5805

About the journal